Skip to content

The effects of creatine supplementation and weight training on muscle mass in individuals with prostate cancer undergoing androgen deprivation therapy.

Examining the effect of creatine supplementation in augmenting adaptations to resistance training in prostate cancer patients undergoing androgen deprivation therapy: a randomized, double-blind, placebo controlled trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12619000099123
Acronym
ProCreat
Enrollment
56
Registered
2019-01-23
Start date
2019-02-13
Completion date
2020-08-27
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to examine the effects of creatine supplementation in conjunction exercise on muscle mass, muscle strength and physical function in prostate cancer patients. Who is it for? You may be eligible for this study if you are aged 18 or over and have localised or locally advanced prostate cancer. Participants must be currently on androgen deprivation therapy and be remaining so for the next three months. Participants will be randomised by chance into two groups. Both groups will partake in a 12 week exercise program targeting the major muscle groups. Sessions will be three times a week and go for approximately an hour. Both groups will also drink a dissolved powder every day for the 12 weeks. One group will drink creatine powder, and the other group will drink dextrose powder (sugar). Participants and researchers will not know which powder each participant is consuming until the end of the study. As part of the study, participants will answer questionnaires, provide a blood sample and do some fitness tests. It is hoped that this research will answer the question if creatine supplementation with weight training can result in greater improvements in muscle mass and strength in men with prostate cancer undergoing androgen deprivation therapy. These results will be important in allowing us to design future studies to further study these questions and ultimately translate these findings into clinical practice.

Interventions

Study Design This is a double-blind randomised controlled trial designed to measure the effects of creatine (Cr) supplementation in addition to resistance training (RT) in prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT). Both supplement (SUPP) and control (PLA) groups will receive a 12-week supervised exercise program comprising of RT undertaken three times per week. In addition, participants in the SUPP group will receive a daily dose of Cr: 20 g/day during the loadi

Study Design This is a double-blind randomised controlled trial designed to measure the effects of creatine (Cr) supplementation in addition to resistance training (RT) in prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT). Both supplement (SUPP) and control (PLA) groups will receive a 12-week supervised exercise program comprising of RT undertaken three times per week. In addition, participants in the SUPP group will receive a daily dose of Cr: 20 g/day during the loading phase, 5g/d thereafter for the duration of the study. The PLA group will also receive a daily dose of a placebo of dextrose (following the same dosing protocol as SUPP). Participants Fifty-six men (n=56) with localised or locally advanced prostate cancer, who are currently on ADT (and expected to remain on ADT for the next three months) will be eligible to enrol in this study. Exercise Program Participants assigned to each arm will attend three (60-minute) clinic-based supervised RT sessions each week, for 12 weeks. RT will be prescribed using repetition maximums (RM), where participants will be required to perform 8 different exercises using major muscle groups (Chest press, Push Up, Seated Row, Shoulder Press, Lat Pulldown, Leg Press, Step Up, Leg Curl) at 8-12 RM (the maximal weight that can be lifted 8 to 12 times each set, equivalent to ~65-85% of 1RM) for 3-4 sets per exercise. Accredited Exercise Physiologists will supervise all exercise sessions. Supplement & Placebo protocol Participants in the SUPP group will receive 20g/day of Cr monohydrate for five days, divided into four equal doses throughout the day in the week prior to the start of the 12-week training program. Participants will then be given single daily doses of 5 grams for the remaining 12 weeks in the study. Participants in the PLA group will follow the same dosing protocol with dextrose. Participants will be asked to dissolve the supplements in 200-300 mL juice to mask the solubility of Cr and taste of dextrose. To increase compliance, participants will be asked to return empty packets to the research team once a week. Supplement packages will be coded so that neither the investigators nor the participants will be aware of contents. Supplementation with Cr or PLA will begin following baseline assessments.

Sponsors

Edith Cowan University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Men with localised or locally advanced prostate cancer, who are currently on ADT (and expected to remain on ADT for the next three months) will be eligible to enrol in this study.

Exclusion criteria

Participants will be excluded if they have any visceral or bone metastases (i.e. advanced, or castrate-resistant prostate cancer); are being treated for any secondary or other cancers.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 20, 2026